Prognostic significance of neutrophil lymphocyte ratio in patients of carcinoma cervix treated with radiotherapy

B. Ali Azher, Niketa Thakur, Sonal Patel
{"title":"Prognostic significance of neutrophil lymphocyte ratio in patients of carcinoma cervix treated with radiotherapy","authors":"B. Ali Azher, Niketa Thakur, Sonal Patel","doi":"10.4103/oji.oji_20_20","DOIUrl":null,"url":null,"abstract":"Background: The elevated neutrophil-to-lymphocyte ratio (NLR) has been identified as a poor prognostic indicator in various malignancies. The progression of malignancies is manifested as alteration in blood counts which can be used as the prognostic markers. Aim: The aim of the present study is to analyze the effect of pretreatment NLR and other hematological variables on progression-free survival (PFS) and overall survival (OS) among cervical cancers patients. Materials and Methods: The present retrospective study enrolled 303 cervical cancer (Stage IIB–IVA) patients treated by radical radiotherapy from January 2016 to December 2018. The pretreatment values of NLR, absolute neutrophil count, and absolute lymphocyte count (ALC) were recorded for each patient and their associations with the clinicopathologic variables, PFS, and OS were analyzed. Results: The optimal cutoff value of NLR was 3.0. The median follow-up period was 19 months. On univariate analysis, PFS rates during the follow-up period were significantly lower in NLR-high versus NLR-low group (P = 0.042) and in low-ALC versus high-ALC group (P = 0.018). Multivariate Cox-proportional hazards model identified NLR and ALC as the strongest prognostic factors for PFS. On univariate analysis, OS was better for patients with the International Federation of Gynecology and Obstetrics Stage IIB versus III–IVA (P = 0.046) and ALC >2000/c.mm versus ≤2000/c.mm (P = 0.050), respectively. None of the hematological variables remained significant for OS on the multivariate analysis. Conclusion: High-NLR is associated with worse survival outcomes in cervical cancer patients. NLR and ALC are the independent prognostic factors for PFS in cervical cancer patients.","PeriodicalId":431823,"journal":{"name":"Oncology Journal of India","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Journal of India","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/oji.oji_20_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The elevated neutrophil-to-lymphocyte ratio (NLR) has been identified as a poor prognostic indicator in various malignancies. The progression of malignancies is manifested as alteration in blood counts which can be used as the prognostic markers. Aim: The aim of the present study is to analyze the effect of pretreatment NLR and other hematological variables on progression-free survival (PFS) and overall survival (OS) among cervical cancers patients. Materials and Methods: The present retrospective study enrolled 303 cervical cancer (Stage IIB–IVA) patients treated by radical radiotherapy from January 2016 to December 2018. The pretreatment values of NLR, absolute neutrophil count, and absolute lymphocyte count (ALC) were recorded for each patient and their associations with the clinicopathologic variables, PFS, and OS were analyzed. Results: The optimal cutoff value of NLR was 3.0. The median follow-up period was 19 months. On univariate analysis, PFS rates during the follow-up period were significantly lower in NLR-high versus NLR-low group (P = 0.042) and in low-ALC versus high-ALC group (P = 0.018). Multivariate Cox-proportional hazards model identified NLR and ALC as the strongest prognostic factors for PFS. On univariate analysis, OS was better for patients with the International Federation of Gynecology and Obstetrics Stage IIB versus III–IVA (P = 0.046) and ALC >2000/c.mm versus ≤2000/c.mm (P = 0.050), respectively. None of the hematological variables remained significant for OS on the multivariate analysis. Conclusion: High-NLR is associated with worse survival outcomes in cervical cancer patients. NLR and ALC are the independent prognostic factors for PFS in cervical cancer patients.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中性粒细胞比例对宫颈癌放疗患者预后的意义
背景:中性粒细胞与淋巴细胞比值(NLR)升高已被确定为各种恶性肿瘤的不良预后指标。恶性肿瘤的进展表现为血细胞计数的改变,可作为预后指标。目的:本研究的目的是分析预处理NLR及其他血液学变量对宫颈癌患者无进展生存期(PFS)和总生存期(OS)的影响。材料与方法:本回顾性研究纳入了2016年1月至2018年12月接受根治性放疗的303例宫颈癌(IIB-IVA期)患者。记录每位患者NLR、绝对中性粒细胞计数、绝对淋巴细胞计数(ALC)的预处理值,并分析其与临床病理变量、PFS、OS的相关性。结果:NLR的最佳临界值为3.0。中位随访期为19个月。单因素分析显示,随访期间,高nlr组与低nlr组的PFS率显著降低(P = 0.042),低alc组与高alc组的PFS率显著降低(P = 0.018)。多变量cox -比例风险模型确定NLR和ALC是PFS的最强预后因素。在单因素分析中,国际妇产联合会IIB期患者的OS优于III-IVA期患者(P = 0.046)和ALC患者(P = 2000/c)。Mm vs≤2000/c。mm (P = 0.050)。在多变量分析中,没有一个血液学变量对OS保持显著性。结论:高nlr与宫颈癌患者较差的生存预后相关。NLR和ALC是宫颈癌患者PFS的独立预后因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
CD8-positive T-cell lymphoma of the thyroid: A rare case Burned-out testicular tumor presenting as cervical and retroperitoneal lymphadenopathy Nasal sebaceous carcinoma: A case treated at a tertiary care center Xanthogranulomatous hypophysitis masquerading as pituitary macroadenoma Cardiotoxicity in breast cancer patients receiving trastuzumab with or without prior anthracycline-based chemotherapy: A prospective study from a tertiary cancer institute at Guwahati, India
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1